Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful faithfully but unsuccessfully to create an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn post, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire employment interview which I came away with a bad viewpoint of the business.

Irony of irony, the poor opinion of mine of the company has grown steadily, though the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the know-how and also associated intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) and the first brand new drug program endorsement ($five million), and also royalty payments of five % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and numerous indications, it has this single therapy and a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, several disease types, multiple publications and multiple presentations.

Can it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the very start of the interest of mine in this business. Judging by the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a classic battleground, or maybe some might say cult stock. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *